Halozyme Therapeutics, Inc. — FY2012 Form 10-K
Reporting period: Fiscal year ended December 31, 2012. This is an annual filing; Q4 figures are noted separately where useful. Halozyme is a biopharmaceutical company developing enzyme-based drug delivery and therapeutic products, with Hylenex recombinant as its marketed product and collaboration revenue as its principal revenue source.
Financial performance and liquidity
| Metric | FY2012 | FY2011 |
|---|---|---|
| Total revenue | $42.3 million | $56.1 million |
| Product sales | $2.9 million | $1.8 million |
| Net loss | $53.6 million | $19.8 million |
| Net loss per share | $0.48 | $0.19 |
| Operating cash used | $64.3 million | $34.4 million |
| Cash and cash equivalents at year-end | $99.9 million | $52.8 million |
| Working capital | $112.1 million | $46.7 million |
| Long-term debt, net | $29.7 million | None reported |
Product cost of sales was $1.1 million, implying product gross profit of approximately $1.8 million before other expenses. The filing does not present a consolidated gross margin that is directly comparable across product and collaboration revenue. Q4 2012 revenue was $21.8 million and net loss was $4.4 million; Q4 revenue included a $9.5 million Pfizer license payment.
At December 31, 2012, total assets were $134.7 million, total liabilities $85.9 million, and stockholders’ equity $48.9 million. The company drew a $30 million secured term loan in December; it bears 7.55% fixed interest, matures January 1, 2017, and includes a $2.55 million final payment. Substantially all assets secure the loan, with intellectual property and specified assets excluded. Management said the company was compliant with material loan covenants at year-end.
Changes versus the prior period
- Revenue fell 25% year over year, largely because 2011 included $18.0 million of upfront payments from ViroPharma and Intrexon and approximately $17.1 million of deferred revenue recognized after termination of the Baxter Hylenex marketing collaboration. FY2012 included $9.5 million from the new Pfizer collaboration.
- Net loss widened substantially as R&D rose to $70.0 million from $57.6 million and SG&A rose to $24.8 million from $18.1 million. R&D growth reflected collaborator-related manufacturing, validation batches and research; insulin-program clinical spending declined.
- Operating cash use increased by $30.0 million, including a $13.4 million increase in accounts receivable. Cash nevertheless rose through $81.5 million of net equity proceeds and $29.7 million of net debt proceeds.
- Hylenex sales increased following its December 2011 market reintroduction, but remain small relative to operating costs. The company completed an $81.5 million net public stock offering in February 2012.
Outlook, developments and risks
- Management estimated 2013 net cash burn of approximately $45–$50 million, depending on program progress, manufacturing scale-up and collaboration milestones. It expected existing cash to fund operations for at least 12 months, but did not expect revenue to fund operations until 2014 at the earliest. Management also cautioned that additional capital may be needed.
- Management expected R&D and commercial spending to increase. It planned to initiate a randomized Phase 2 PEGPH20 study with gemcitabine and Abraxane in the first half of 2013, and expected HTI-501 Phase 2 data in the first half of 2013. The filing gives no formal revenue or earnings guidance.
- Roche submitted European applications for subcutaneous Herceptin and MabThera; Roche reported positive Phase 3 Herceptin SC results and positive first-stage MabThera SC results. These are collaborator programs, not Halozyme-approved products.
- The FDA issued Baxter a complete response letter for HyQ, requesting additional preclinical data concerning non-neutralizing anti-rHuPH20 antibodies and potential reproductive, developmental and fertility effects; dosing in Baxter’s program was paused pending data. The FDA said no action was required against Hylenex or other programs under the Drug Division. ViroPharma’s Cinryze program, temporarily held, was permitted to resume with enhanced antibody monitoring.
- Key business risks include reliance on collaborators and rHuPH20, clinical and regulatory uncertainty, concentrated revenue and receivables, third-party manufacturing capacity and quality, and dependence on external financing. Roche and Baxter represented 45% and 17% of FY2012 revenue, respectively; Pfizer contributed 22%. Roche and Pfizer together represented approximately 86% of year-end receivables.
- The company reported no legal proceedings expected by management to have a material adverse effect. Its financial statements received an unqualified audit opinion, and management and the auditor concluded internal control over financial reporting was effective.
Most important facts for investors to verify
- Progress and timing of FDA-requested HyQ preclinical work, and whether antibody-related concerns affect other rHuPH20 programs.
- Actual 2013 cash burn, operating runway, and whether further equity or debt financing is required.
- Collaborator regulatory decisions and clinical outcomes, especially Roche’s subcutaneous products and ViroPharma’s Cinryze program.
- Hylenex sell-through, returns and chargebacks: the company deferred some shipments pending reliable estimates of channel sales and product returns.
- Manufacturing readiness, minimum purchase commitments and continuity of supply from contract manufacturers.